Authors: Anne M Durkan Laura E Keating Annette Vigneux Denis F Geary
Publish Date: 2006/03/25
Volume: 21, Issue: 5, Pages: 694-
Abstract
Darbepoetin is a newer analogue of epoetin with a longer halflife that allows less frequent administration There are currently no published data available for its use in infants We report our experience with this drug in infants with chronic renal impairment weighing less than 8 kg Infants had baseline haemoglobin Hb iron ferritin and transferrin levels measured They were started on approximately 05 μg/kg per week of darbepoetin Hb levels were checked every 2–4 weeks and iron studies were performed every 4 weeks Iron supplementation was prescribed to maintain ferritin levels 100 μg/l and transferrin saturation levels 20 Follow up was for 20 weeks Six infants with a mean weight of 408 kg and a mean creatinine of 259 μmol/l were included Three infants were medically stable throughout the study and the mean darbepoetin dose was decreased to 025 μg/kg per week Their dosing interval was increased to every 3–4 weeks The other three infants were less stable and had multiple medical problems including periods of haemodialysis and surgery These infants failed to reach target Hb level despite an increase in the mean dose of darbepoetin to 12 μg/kg per week In conclusion darbepoetin can be successfully administered to infants with chronic renal insufficiency but the dose needs to be tailored to each individual Administration would be facilitated by smaller unidose syringes
Keywords: